Crossroads in the evaluation of paraoxonase 1 for protection against nerve agent and organophosphate toxicity.
Human paraoxonase 1 (PON1), a 45kDa arylesterase associated with circulating high density lipoproteins (HDL), has been described as an anti-atherogenic element in cardiovascular disorders. The efficacy of PON1 as a catalytic bioscavenger against OP and CWNA toxicity has been on debate for the last few decades. Hydrolysis of various organophosphates (OPs) and chemical warfare nerve agents (CWNAs) by PON1 has been demonstrated in both in vitro and in vivo experiments. Recently, we established the protective efficacy of human and rabbit serum purified PON1 as well as human recombinant PON1 expressed in Trichoplusia ni larvae against nerve agent toxicity in guinea pigs. Exogenous administration of purified PON1 was effective in protecting against 1.2 X LCt(50) of sarin and soman administered endotracheally with microinstillation technology. However, the short half-life of exogenously administered PON1, probably due to poor association with circulating HDL, warrant alternative approaches for successful utility of PON1 in the treatment of OP/CWNA toxicity. In this mini review, we address the pros and cons of current PON1 prophylaxis and propose potential solutions for successful development of PON1 as an effective catalytic bioscavenger.
Blast-Induced Neurotrauma Branch, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Manojkumar
M
Valiyaveettil
Yonas A
YA
Alamneh
Bhupendra P
BP
Doctor
Madhusoodana P
MP
Nambiar
D000818:Animals; D043303:Aryldialkylphosphatase / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002619:Chemical Warfare Agents / Q000378:metabolism*; D006168:Guinea Pigs; D006207:Half-Life; D006801:Humans; D010755:Organophosphates / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011817:Rabbits
D002619:Chemical Warfare Agents; D010755:Organophosphates; D043303:Aryldialkylphosphatase